Related Experiment Videos
Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients
1Rambam Medical Center, Rappaport Institute for Research in the Medical Sciences, The Bruce Rappaport Technion Faculty of Medicine, Haifa, Israel.
Insights
Fosinopril, an angiotensin-converting enzyme (ACE) inhibitor, significantly reduces adenosine diphosphate (ADP)-induced platelet aggregation in hypertensive patients. This effect was observed both in vivo and in vitro, suggesting a potential therapeutic benefit in cardiovascular disease.
Area of Science:
- Cardiovascular Pharmacology
- Hematology
Background:
- Platelets play a key role in atherosclerosis.
- Hypertension is a significant risk factor for coronary artery disease.
- Angiotensin-converting enzyme (ACE) inhibitors are known to manage hypertension and atherosclerosis.
Purpose of the Study:
- To investigate the effect of the novel ACE inhibitor, fosinopril, on platelet aggregation in hypertensive patients.
- To determine if fosinopril inhibits adenosine diphosphate (ADP)-induced platelet aggregation.
Main Methods:
- A study involving 18 male hypertensive patients treated with 10 mg/day of fosinopril for 4 weeks.
- In vitro experiments to assess fosinopril's effect on platelet aggregation using ADP and collagen as aggregating agents.
Main Results:
- Fosinopril therapy resulted in a reduction of at least 31% in ADP-induced platelet aggregation.
- In vitro studies confirmed fosinopril's inhibitory effect on ADP-induced platelet aggregation.
- Fosinopril did not show inhibitory effects when collagen was used as the aggregating agent.
Conclusions:
- Fosinopril demonstrates significant inhibitory activity against ADP-induced platelet aggregation.
- The inhibitory effect of fosinopril on platelet aggregation was more pronounced in platelets from normal subjects compared to those from hypertensive patients.
- Fosinopril shows potential as a therapeutic agent for managing platelet-related complications in hypertensive individuals.
Abstract:
Platelets are intimately involved in atherosclerosis, and hypertension is a known risk factor for coronary artery disease. The angiotensin-converting enzyme (ACE) inhibitors were demonstrated to reduce hypertension and attenuate atherosclerosis. Because increased platelet aggregation was shown in hypertensive patients, the effect of a new ACE inhibitor, fosinopril, on platelet aggregation was studied. Fosinopril therapy (10 mg/day for 4 weeks) in 18 male hypertensive patients showed > or = 31% reduction in ADP-induced platelet aggregation. In vitro studies showed that fosinopril had similar inhibitory effect on ADP-induced platelet aggregation. No inhibitory effect could be detected with collagen as the aggregating agent. Finally, inhibition of platelet aggregation by fosinopril was less effective in platelets derived from hypertensive patients as compared with platelets derived from normal subjects. We conclude that fosinopril possesses a significant inhibitory activity on ADP-induced platelet aggregation both in vitro and in vivo.